
Sign up to save your podcasts
Or


Solving More Than Science with Adrienne Mendoza
Cell and gene therapy is advancing rapidly, but science alone isn’t enough.
In this episode of She Leads Biotech, Adrienne Mendoza, Chief Operating Officer of BBG Advanced Therapies, shares what’s really needed to move the field forward, from improving access and infrastructure to rethinking how these therapies reach patients.
We also explore her journey over the past year, building a stronger presence in the industry, translating complex science for broader audiences, and the realities of leading through a challenging and evolving market.
A practical and honest look at where the field is today, and what it will take to get to the next stage.
Chapters
00:00 Introduction
02:00 Stepping into a New Role at BBG Advanced Therapies
05:00 How the Role of a COO Evolves
08:30 Building Presence and Community in CGT
12:00 Making Complex Science Understandable
16:00 The Mobile Leukapheresis Bus
21:00 Access Challenges in Cell & Gene Therapy
27:00 What Needs to Change in the System
33:00 Industry Challenges and Optimism
38:00 What the Next 5 Years Could Look Like
41:00 Life Outside of Biotech
#SheLeadsBiotech #CellAndGeneTherapy #BiotechLeadership #LifeSciences #CNAUSAExecutiveSearch
Rethinking Eye Care: From NanoDropper to Mu Medical
What started as a student project has turned into a company reshaping how eye care is delivered.
In this episode of She Leads Biotech, we’re joined by Allisa Song, CEO of Mu Medical, and Mackenzie Andrews, CCO, to talk about the journey from an idea sparked in a research lab to a product now used across thousands of clinics.
They share how a simple question, why are eye drops too big, led to a solution that improves patient outcomes, reduces waste, and is now evolving into something much bigger.
We also get into co-founder dynamics, building in a complex healthcare system, and the reality of being young female leaders in a traditionally male-dominated space.
A practical, honest conversation about building, scaling, and challenging assumptions in healthcare.
Chapters
00:00 Introduction
01:30 Meet Allisa & Mackenzie
04:00 From Research Lab to Startup Idea
08:30 The Eye Drop Problem Explained
13:00 Building NanoDropper
18:30 When It Became a Real Business
22:00 Product Demo & Clinical Impact
26:00 Go-to-Market Strategy
30:00 Working with Insurers, Clinics & Pharma
34:00 Evolving into Mu Medical
38:00 Co-Founder Dynamics & Trust
42:00 Being Women in a Male-Dominated Industry
47:00 Advice for Founders
51:00 What’s Next for Mu Medical
Listen / Watch:
Spotify | YouTube
#SheLeadsBiotech #MedTech #HealthcareInnovation #WomenInBiotech #CNAUSAExecutiveSearch
Finding Your Path in Biotech with Connie Chang
Careers in biotech rarely follow a straight line.
In this episode of She Leads Biotech, we speak with Connie Chang, Chief Operating Officer of ONL Therapeutics, about a career that has spanned big pharma, academia, and emerging biotech, and how each step has shaped the way she leads today.
Connie shares how early career decisions don’t always define where you end up, and why sometimes “the career picks you” rather than the other way around.
We explore the reality of moving between very different environments, from highly structured global organizations to small, fast-moving biotech companies, and what it really takes to adapt and succeed in both.
This conversation also highlights the importance of community throughout your career, the role academia plays in driving innovation, and the personal side of leadership, including navigating family decisions, career risks, and the pressure many women face as they progress into senior roles.
A thoughtful and honest discussion on building a career, leading with intention, and continuing to grow, even when you’re already at the top.
Chapters
00:00 Introduction
01:30 How Connie Found Biotech
04:00 Harvard, Community, and Early Influences
06:30 Big Pharma, Academia, and Connecting the Dots
10:00 Taking Career Risks and Moving to Michigan
14:30 ONL Therapeutics and the Mission Behind the Science
18:00 What a COO Role Really Looks Like in Biotech
20:30 Building Teams in Small Biotech
23:00 Leadership Style and Creating Trust
26:00 Adapting Across Cultures and Environments
29:00 Women in Leadership and Career Progression
32:00 Being the Only One at the Table
35:00 Self-Doubt, Growth, and Resilience
37:30 What’s Next for ONL and Connie
#SheLeadsBiotech #BiotechLeadership #WomenInBiotech #LifeSciences #CNAUSAExecutiveSearch
Leading Women’s Health Innovation: From Clinical Practice to CEO with Mandy Pulliam
In this episode of She Leads Biotech, I’m joined by Samantha (Mandy) Pulliam, CEO and Chief Medical Officer at Axena Health, for a conversation that highlights what it really takes to lead in women’s health.
Mandy’s journey is a unique one. She started her career as a practicing physician before stepping into the biotech and medtech space, bringing with her a deep understanding of patient care that continues to shape how she leads today.
What stood out to me in this conversation is how intentional she has been about bridging clinical insight with innovation. At Axena Health, she’s focused on addressing conditions that have historically been under-discussed and underserved, particularly in pelvic health.
We talk about the realities of building and leading in women’s health, where the need is significant, but awareness, funding, and attention have often lagged behind.
Mandy shares how she approaches leadership as both a clinician and a CEO, how she thinks about patient impact alongside commercial success, and why creating solutions in this space requires both persistence and a willingness to challenge long-standing assumptions.
This is a conversation about leadership, purpose, and the responsibility that comes with developing products that directly impact patients’ quality of life.
And a reminder that innovation in healthcare isn’t just about new technology, it’s about truly understanding the people you’re trying to help.
📌 Chapters
00:00 Introduction
01:48 Mandy’s journey from physician to CEO
03:52 Moving from clinical practice into industry
05:41 Why women’s health remains underserved
07:32 The mission behind Axena Health
09:18 Addressing pelvic health challenges
11:05 Bridging patient care and innovation
13:12 Leadership as both a clinician and executive
15:20 Navigating funding and awareness gaps
17:08 Building solutions that truly serve patients
19:06 Commercial strategy in women’s health
21:14 Lessons learned stepping into the CEO role
23:02 Advice for women entering biotech leadership
24:40 Balancing purpose with business outcomes
26:18 The future of women’s health innovation
🎙️ She Leads Biotech celebrates the journeys of women shaping the future of life sciences.
Subscribe for more conversations with biotech leaders, founders, and innovators.
#SheLeadsBiotech #WomensHealth #BiotechLeadership #LifeSciences #MedTech #WomenInBiotech #HealthcareInnovation #CNAUSAExecutiveSearch
Rethinking Rare Disease: A New Model for Ultra-Rare Therapies with Beth White
In this episode of She Leads Biotech, I’m joined by Elizabeth (Beth) White, COO and Co-Founder of Orphan Therapeutics Accelerator, for a conversation that really stayed with me.
Beth has spent her career at the intersection of science, strategy, and commercialization, and today she’s focused on one of the biggest challenges in our industry: how do we bring therapies to patients with ultra-rare diseases when the traditional biotech model simply doesn’t support them?
As Beth explains, the science has moved forward, especially in gene and cell therapies, but the business model hasn’t kept up. And that’s leaving too many promising therapies sitting on the shelf, never reaching the patients who need them.
What she and her team are building with the Orphan Therapeutics Accelerator is a completely different approach. A nonprofit biotech model designed to rethink how therapies are funded, developed, and ultimately delivered to patients.
We talk about what that actually looks like in practice, from new ways of funding and partnering, to the creation of the CGT Exchange, a marketplace designed to unlock shelved assets and give them a path forward.
This is one of those conversations that really challenges how you think about drug development, investment, and impact.
And a reminder that behind every “ultra-rare” disease are real patients, real families, and a very real urgency to find solutions.
📌 Chapters
00:00 Introduction
01:52 Why ultra-rare diseases remain underserved
03:44 What the Orphan Therapeutics Accelerator is
05:00 Building a completely new development model
06:32 How the nonprofit structure works in practice
08:39 Creating awareness and industry engagement
10:34 Major partnerships and recent momentum
11:39 What the CGT Exchange is and why it matters
13:26 Can this model work at scale?
15:08 Beth’s journey into rare disease and gene therapy
17:01 Bridging science and business
19:18 Leadership across pharma, biotech, and nonprofit
21:19 Big pharma vs biotech mindset
23:09 Leading with limited resources
24:21 Advice for women in biotech
25:37 Risk-taking and career decisions
26:17 The future of rare disease development
28:40 The role of AI in accelerating progress
🎙️ She Leads Biotech celebrates the journeys of women shaping the future of life sciences.
Subscribe for more conversations with biotech leaders, founders, and innovators.
#SheLeadsBiotech #BethWhite #RareDisease #GeneTherapy #BiotechInnovation #WomenInBiotech #LifeSciences #CNAUSAExecutiveSearch
From Data to Discovery: Accelerating Drug Development with Samantha Dale Strasser
In this episode of She Leads Biotech, I sit down with Samantha Dale Strasser, VP of Strategy at Cellular Intelligence, for a fascinating conversation at the intersection of biology, computation, and patient impact.
Samantha’s journey spans biomedical engineering, applied mathematics, physics, and a PhD at MIT, but what truly shaped her path was something deeply personal. Her father’s diagnosis with frontotemporal dementia brought into sharp focus just how far we still have to go in treating complex diseases, and sparked a determination to accelerate how we move new technologies from the lab into the hands of patients.
We talk about her transition from academia into entrepreneurship, co-founding PepperBio, and now her work at Cellular Intelligence, where she is helping to build a platform that is fundamentally changing how we ask and answer biological questions.
What stood out to me in this conversation is just how much the pace of science is shifting. Questions that once took years to answer can now be explored in months, opening up entirely new possibilities for drug discovery and treatment.
We also dive into leadership, resilience, and what it really takes to build something from scratch in uncertain times.
📌 Chapters
00:00 Introduction
00:10 Samantha’s background and academic journey
02:10 Early interest in biology and computation
04:15 A personal turning point: her father’s diagnosis
05:32 Founding PepperBio and early entrepreneurship
06:35 What Cellular Intelligence is building
09:39 The role of AI and large-scale data in biology
10:43 How speed is transforming research timelines
11:41 Building a tech bio company
13:26 Leadership across different stages of her career
15:21 Motivating and growing scientific teams
16:44 Transitioning from operator to leader
18:29 The leadership training gap in life sciences
20:34 Resilience and building a company during COVID
23:44 Advice for scientists interested in entrepreneurship
26:19 What the future holds for Samantha and the field
28:00 A personal mission and long-term vision
🎙️ She Leads Biotech celebrates the journeys of women shaping the future of life sciences.
Subscribe for more conversations with biotech leaders, founders, and innovators.
#SheLeadsBiotech #SamanthaDaleStrasser #CellularIntelligence #BiotechInnovation #DrugDiscovery #WomenInBiotech #LifeSciences #CNAUSAExecutiveSearch
In this episode of She Leads Biotech, Sharron Cox speaks with Joanna Ghayad, Founder & CEO of Joanna Ghayad Coaching, about leadership, influence, and the transition many scientists struggle to make as their careers grow.
Joanna’s career has taken her from working as an oncology pharmacist supporting cancer patients at the bedside, to roles in biotech and big pharma, and ultimately to launching her own leadership coaching practice focused on developing the next generation of leaders in life sciences.
After more than 15 years working across healthcare, biotech, and large pharmaceutical organizations, Joanna began to notice a consistent gap. Scientists are trained extensively in technical expertise, but very rarely taught how to lead teams, influence decisions, and communicate science in a way that drives business and patient impact.
In this conversation we explore the shift from technical expert to strategic leader, why scientists often get “boxed in,” and how professionals in life sciences can take ownership of their careers rather than waiting for someone else to define the next step.
Joanna also shares practical advice for scientists who want to grow their influence, build visibility within their organizations, and develop the leadership skills needed to move into executive roles.
If you're working in biotech, pharma, or the broader life sciences ecosystem and thinking about your next step, this is a conversation worth listening to.
Connect with Joanna Ghayad
LinkedIn: Joanna Ghayad
YouTube: The Revolutionary Stemmist
Joanna has also generously offered listeners a complimentary 20-minute coaching session, available through the link below: https://joannaghayadcoaching.com/conference/form
Chapters
00:00 Introduction
01:34 Joanna’s journey into pharmacy and oncology
03:33 Exploring career paths during pharmacy school
05:08 Transitioning from healthcare into biotech and pharma
09:08 Discovering the leadership gap in life sciences
10:30 Creating leadership training inside big pharma
13:38 Why scientists struggle with leadership and influence
16:08 The myth that scientists aren’t creative
20:40 Launching Joanna Ghayad Coaching
23:35 Moving from operator to leader
26:13 How coaching helps scientists advance their careers
28:20 Advice for scientists who want to grow into leadership
32:03 Navigating power dynamics in organizations
35:11 Authentic leadership and building respect
37:46 How to connect with Joanna
Megan McGill | Leadership, Credibility & Persistence in Biotech
CEO, Brenig Therapeutics
What does it really take to build credibility as a leader in biotech?
In this episode of She Leads Biotech, I sit down with Megan McGill, CEO of Brenig Therapeutics, to talk about leadership, persistence, and the realities women still face when building careers in the life sciences industry.
Megan shares her journey into biotech leadership and what it takes to step into the CEO role in a competitive and evolving sector.
One part of our conversation that really stood out was Megan’s honesty about something many women quietly experience: sometimes you have to outperform everyone else just to be taken seriously.
We talk about the importance of credentials, preparation, and resilience, and why continuing to push forward matters, even when the room isn’t designed with you in mind.
This conversation is an honest look at leadership, credibility, and the persistence required to succeed in biotech.
Chapters:
00:00 Introduction
01:45 Megan’s career journey into biotech
07:30 Moving into leadership roles
13:10 The reality of credibility and gender bias
18:20 Why credentials matter in leadership
24:15 Advice for women building careers in biotech
29:40 Leadership lessons as CEO of Brenig Therapeutics
34:30 Final advice for the next generation
🎙️ She Leads Biotech celebrates the journeys of women shaping the future of life sciences.
Subscribe for more conversations with biotech leaders, founders, and innovators.
#SheLeadsBiotech #MeganMcGill #BrenigTherapeutics #BiotechLeadership #WomenInBiotech #WomenInScience #LifeSciences
What does it really take to move from academia to industry… and then into the C-suite?
In this episode of She Leads Biotech, I sit down with Sailaja Battula, Chief Scientific Officer at Ankyra Therapeutics, whose journey is anything but conventional.
Born and raised on a farm in South India, Sailaja became the first in her family to attend college. She completed her PhD while raising two young children, applied for over 200 industry roles to make her transition, built immunology teams from scratch, and ultimately stepped into the CSO role at a pivotal moment for her company.
This is a conversation about intention, discipline, leadership growth, and knowing when you are ready, even before you fully believe it yourself.
We cover:
• Transitioning from academia to industry
• What hiring managers really look for
• Building and leading discovery teams
• Moving from VP to CSO
• Leadership vs management in scientific roles
• Raising a family while building a biotech career
If you are thinking about your next move, especially into leadership, this episode is packed with clarity and practical insight.
Chapters:
00:00 Introduction
01:40 Growing up on a farm in South India
07:01 Education, marriage, and moving to the US
08:48 Breaking into biotech with a newborn
11:19 PhD, postdoc, and moving into immuno-oncology
14:37 Why transitioning from academia to industry is hard
19:21 The three questions to ask before applying for a role
22:46 Career progression from scientist to VP
30:12 Stepping into the CSO role at Ankyra
36:16 What changes when you join the C-suite
38:10 Leadership vs management in science
40:38 Advice to her younger self
42:03 Using LinkedIn strategically for career growth
43:42 What’s next as CSO
🎙️ Subscribe for more conversations with women shaping the future of biotech.
#SheLeadsBiotech #SailajaBattula #AnkyraTherapeutics #ChiefScientificOfficer #BiotechLeadership #WomenInScience #CNAUSAExecutiveSearch
In this episode of She Leads Biotech, I sit down with Mori Mohseni, Head of Biology at VidaVinci, for a powerful conversation about persistence, purpose, and what it really takes to lead in drug discovery.
From her early fascination with biology to pivotal roles at AstraZeneca, Novartis, BMS, and now startup biotech, Mori’s career has been defined by one recurring theme: give her the hard problem.
We talk about what it means to search for truth in science, even when the answer isn’t what you hoped for. We explore the transition from big pharma to biotech to startup life, and why those moves were intentional. And we dive into leadership, team building, and the obsession required to move breakthrough science forward.
This is a conversation about loving the work enough to stay with it when it’s difficult, and inspiring others to do the same.
📌 Chapters / Timestamps
00:00 – Introduction and Mori’s early path into science
03:40 – Falling in love with biology and choosing research over medicine
08:10 – The leap from academia into industry
12:00 – A pivotal lesson: “Look for the truth” in drug discovery
15:20 – Seeing a drug go from bench to patient
18:45 – Big pharma vs biotech vs startup: what really changes
23:15 – Building infrastructure from scratch in smaller companies
27:30 – Leading as a servant leader and building strong teams
31:40 – Advice for young scientists navigating today’s market
35:50 – The future of biotech and the need for early innovation funding
40:10 – Leadership in biotech means loving what you do
From the publisher's feed